{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:52:22Z","timestamp":1790419942272,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32470-B"],"award-info":[{"award-number":["P32470-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Mast cell (MC) activation syndromes (MCAS) are conditions defined by recurrent episodes of severe systemic anaphylaxis or similar systemic events triggered by MC-derived mediators that can be measured in biological fluids. Since some symptoms of MC activation may occur due to other, non-MC etiologies and lead to confusion over diagnosis, it is of crucial importance to document the involvement of MC and their products in the patients\u00b4 symptomatology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>The most specific and generally accepted marker of severe systemic MC activation is an event-related, transient increase in the serum tryptase level over the individual baseline of the affected individual. However, baseline concentrations of serum tryptase vary among donors, depending on the genetic background, age, kidney function, and underlying disease. As a result, it is of critical importance to provide a flexible equation that defines the diagnostic increase in tryptase qualifying as MCAS criterion in all patients, all situations, and all ranges of baseline serum tryptase. In 2012, the consensus group proposed the 120%\u2009+\u20092 ng\/ml formula, which covers the great majority of groups, including cases with low, normal, or elevated basal serum tryptase level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This formula has been validated in subsequent studies and has proven to be a robust and consistent diagnostic criterion of MCAS. The present article is discussing the impact of this formula and possible limitations as well as alternative markers and mediators that may be indicative of MCAS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-024-01124-2","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T03:02:51Z","timestamp":1706929371000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?"],"prefix":"10.1007","volume":"24","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"1124_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946\u201356.","journal-title":"Blood"},{"key":"1124_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18:693\u2013704.","journal-title":"Nat Med"},{"key":"1124_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373:163\u201372.","journal-title":"N Engl J Med"},{"key":"1124_CR4","doi-asserted-by":"publisher","first-page":"10743","DOI":"10.7150\/thno.46719","volume":"10","author":"P Valent","year":"2020","unstructured":"\u2022 Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich\u2019s visions to precision medicine concepts. Theranostics. 2020;10:10743\u201368. This article describes that the mast cell system forms a unique hematopoietic cell lineage with unique features and unique functional properties in health and disease.","journal-title":"Theranostics"},{"key":"1124_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","volume":"18","author":"P Valent","year":"2023","unstructured":"\u2022 Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol. 2023;18:361\u201386. Comprehensive review on the pathogenesis and pathology of mast cells in patients with mast cell proliferative disorders (mastocytosis) and mast cell activation disorders.","journal-title":"Annu Rev Pathol"},{"key":"1124_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jaci.2009.08.035","volume":"124","author":"DD Metcalfe","year":"2009","unstructured":"Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol. 2009;124:639\u201346.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000315937","volume":"95","author":"J Kalesnikoff","year":"2010","unstructured":"Kalesnikoff J, Galli SJ. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol Allergy. 2010;95:45\u201366.","journal-title":"Chem Immunol Allergy"},{"key":"1124_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.anai.2017.01.009","volume":"118","author":"P Lieberman","year":"2017","unstructured":"Lieberman P. Mechanisms of anaphylaxis beyond classically mediated antigen- and IgE-induced events. Ann Allergy Asthma Immunol. 2017;118:246\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1124_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","volume":"38","author":"SJ Galli","year":"2020","unstructured":"Galli SJ, Gaudenzio N, Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol. 2020;38:49\u201377.","journal-title":"Annu Rev Immunol"},{"key":"1124_CR10","first-page":"90","volume":"27","author":"LB Schwartz","year":"1990","unstructured":"Schwartz LB. Tryptase from human mast cells: biochemistry, biology and clinical utility. Monogr Allergy. 1990;27:90\u2013113.","journal-title":"Monogr Allergy"},{"key":"1124_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0091-6749(05)80222-2","volume":"86","author":"LB Schwartz","year":"1990","unstructured":"Schwartz LB. Tryptase, a mediator of human mast cells. J Allergy Clin Immunol. 1990;86:594\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR12","first-page":"11939","volume":"256","author":"LB Schwartz","year":"1981","unstructured":"\u2022 Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterization J Biol Chem. 1981;256:11939\u201343. Isolation and biochemical characterization of human tryptase from tissue mast cells.","journal-title":"Purification and characterization J Biol Chem"},{"key":"1124_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2004.02.032","volume":"113","author":"S Jogie-Brahim","year":"2004","unstructured":"Jogie-Brahim S, Min HK, Fukuoka Y, Xia HZ, Schwartz LB. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol. 2004;113:1086\u201392.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR14","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","volume":"170","author":"LB Schwartz","year":"2003","unstructured":"Schwartz LB, Min HK, Ren S, Xia HZ, Hu J, Zhao W, et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J Immunol. 2003;170:5667\u201373.","journal-title":"J Immunol"},{"key":"1124_CR15","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.4049\/jimmunol.176.5.3165","volume":"176","author":"Y Fukuoka","year":"2006","unstructured":"Fukuoka Y, Schwartz LB. The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH. J Immunol. 2006;176:3165\u201372.","journal-title":"J Immunol"},{"key":"1124_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.578","volume":"10","author":"BR Skarb\u00f8","year":"2022","unstructured":"Skarb\u00f8 BR, Vinnes EW, Wentzel-Larsen T, Sylte MS, Apelseth TO. Estimating the within-subject (CVI) and between-subject (CVG) biological variation of serum tryptase. Immun Inflamm Dis. 2022;10: e578.","journal-title":"Immun Inflamm Dis"},{"key":"1124_CR17","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","volume":"7","author":"J Chovanec","year":"2023","unstructured":"Chovanec J, Tunc I, Hughes J, Halstead J, Mateja A, Liu Y, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv. 2023;7:1796\u2013810.","journal-title":"Blood Adv"},{"key":"1124_CR18","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.jaip.2023.08.008","volume":"11","author":"P Valent","year":"2023","unstructured":"\u2022 Valent P, Hoermann G, Bonadonna P, Hartmann K, Sperr WR, Broesby-Olsen S, et al. The normal range of baseline tryptase should be 1 to 15 ng\/mL and covers healthy individuals with H\u03b1T. J Allergy Clin Immunol Pract. 2023;11:3010\u201320. Description of biological ranges of basal serum tryptase in healthy subjects, including cohorts with or without carriers of hereditary alpha tryptasemia.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000059404","volume":"128","author":"WR Sperr","year":"2002","unstructured":"Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002;128:136\u201341.","journal-title":"Int Arch Allergy Immunol"},{"key":"1124_CR20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/10428190290021470","volume":"43","author":"WR Sperr","year":"2002","unstructured":"Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma. 2002;43:1097\u2013105.","journal-title":"Leuk Lymphoma"},{"key":"1124_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1365-2362.2009.02184.x","volume":"39","author":"WR Sperr","year":"2009","unstructured":"Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical hematology. Eur J Clin Invest. 2009;39:914\u201323.","journal-title":"Eur J Clin Invest"},{"key":"1124_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1586\/17474086.2014.955008","volume":"7","author":"P Valent","year":"2014","unstructured":"Valent P, Sperr WR, Sotlar K, Reiter A, Akin C, Gotlib J, et al. The serum tryptase test: an emerging robust biomarker in clinical hematology. Expert Rev Hematol. 2014;7:683\u201390.","journal-title":"Expert Rev Hematol"},{"key":"1124_CR23","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","volume":"316","author":"LB Schwartz","year":"1987","unstructured":"\u2022\u2022 Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316:1622\u20136. First description that an event-related elevation of serum tryptase over the individual\u00b4s baseline is a robust biochemical marker of anaphylaxis.","journal-title":"N Engl J Med"},{"key":"1124_CR24","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1172\/JCI118337","volume":"96","author":"LB Schwartz","year":"1995","unstructured":"Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest. 1995;96:2702\u201310.","journal-title":"J Clin Invest"},{"key":"1124_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0091-6749(95)70139-7","volume":"95","author":"HJ Schwartz","year":"1995","unstructured":"Schwartz HJ. Elevated serum tryptase in exercise-induced anaphylaxis. J Allergy Clin Immunol. 1995;95:917\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","volume":"26","author":"LB Schwartz","year":"2006","unstructured":"Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26:451\u201363.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1124_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1067\/mai.2000.107600","volume":"106","author":"RY Lin","year":"2000","unstructured":"Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol. 2000;106:65\u201371.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI114051","volume":"83","author":"LB Schwartz","year":"1989","unstructured":"\u2022 Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83:1551\u20135. Detailed analysis of the time course of serum tryptase levels before, during, and after an anaphylactic event in patients suffering from anaphylaxis.","journal-title":"J Clin Invest"},{"key":"1124_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","volume":"126","author":"C Akin","year":"2010","unstructured":"\u2022 Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126:1099\u2013104. This manuscript presents a first proposal for diagnostic criteria and a classification of mast cell activation syndromes.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","volume":"128","author":"MJ Hamilton","year":"2011","unstructured":"Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128:147-52.e2.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000328760","volume":"157","author":"P Valent","year":"2012","unstructured":"\u2022\u2022 Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215\u201325. This manuscript provides definitions, diagnostic criteria, and a classification of mast cell activation syndromes in a consensus proposal.","journal-title":"Int Arch Allergy Immunol"},{"key":"1124_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/all.12126","volume":"68","author":"P Valent","year":"2013","unstructured":"Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68:417\u201324.","journal-title":"Allergy"},{"key":"1124_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-33.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR34","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","volume":"10","author":"P Valent","year":"2022","unstructured":"\u2022 Valent P, Hartmann K, Bonadonna P, G\u00fclen T, Brockow K, Alvarez-Twose I, et al. Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM consortium. J Allergy Clin Immunol Pract. 2022;10:1941\u201350. This manuscript provides a global classification and diagnostic criteria for mast cell activation disorders, including mast cell activation syndromes (MCAS) and mast cell activation disorders\/conditions in which MCAS criteria are not fulfilled.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR35","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","volume":"11","author":"JH Butterfield","year":"2023","unstructured":"Butterfield JH. Increased excretion of mast cell mediator metabolites during mast cell activation syndrome. J Allergy Clin Immunol Pract. 2023;11:2542\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","volume":"149","author":"MB Chollet","year":"2022","unstructured":"Chollet MB, Akin C. Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. J Allergy Clin Immunol. 2022;149:728-35.e2.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR37","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-de-Olano D, Navarro-Navarro P, Mu\u00f1oz-Gonz\u00e1lez JI, S\u00e1nchez-Mu\u00f1oz L, Henriques A, de-Andr\u00e9s-Mart\u00edn A, et al. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals. Allergy. 2024.","DOI":"10.1111\/all.15911"},{"key":"1124_CR38","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"\u2022 Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564\u20139. This manuscript describes that increased TPSAB1 gene copy numbers are often found in individuals with an elevated basal serum tryptase level.","journal-title":"Nat Genet"},{"key":"1124_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gim.2017.136","volume":"20","author":"JJ Lyons","year":"2018","unstructured":"Lyons JJ, Stotz SC, Chovanec J, Liu Y, Lewis KL, Nelson C, et al. A common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number. Genet Med. 2018;20:503\u201312.","journal-title":"Genet Med"},{"key":"1124_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","volume":"38","author":"V Sabato","year":"2018","unstructured":"\u2022 Sabato V, Chovanec J, Faber M, Milner JD, Ebo D, Lyons JJ. First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease. J Clin Immunol. 2018;38:457\u20139. This manuscript describes multiple TPSAB1 gene copy numbers in a family with mast cell activation symptoms and one case with clonal mast cell disease.","journal-title":"J Clin Immunol"},{"issue":"20","key":"1124_CR41","first-page":"31029","volume":"S0091\u20136749","author":"JJ Lyons","year":"2020","unstructured":"Lyons JJ, Chovanec J, O\u2019Connell MP, Liu Y, \u0160elb J, Zanotti R, et al. Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2020;S0091\u20136749(20):31029.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.2020006157","volume":"137","author":"G Greiner","year":"2021","unstructured":"\u2022\u2022 Greiner G, Sprinzl B, G\u00f3rska A, Ratzinger F, Gurbisz M, Witzeneder N, et al. Hereditary \u03b1 tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021;137:238\u201347. This manuscript describes an association between systemic mastocytosis (SM), severe mediator-related symptoms and hereditary alpha tryptasemia (H\u03b1T). In addition, this manuscript shows that the prevalence of H\u03b1T is significantly higher in SM compared to healthy controls or patients with other hematologic neoplasms.","journal-title":"Blood"},{"key":"1124_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1610-0387.2005.05706.x","volume":"3","author":"S Dugas-Breit","year":"2005","unstructured":"Dugas-Breit S, Sch\u00f6pf P, Dugas M, Schiffl H, Ru\u00ebff F, Przybilla B. Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges. 2005;3:343\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1124_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/eci.12622","volume":"46","author":"MD Jesky","year":"2016","unstructured":"Jesky MD, Stringer SJ, Fenton A, Ng KP, Yadav P, Ndumbo M, et al. Serum tryptase concentration and progression to end-stage renal disease. Eur J Clin Invest. 2016;46:460\u201374.","journal-title":"Eur J Clin Invest"},{"key":"1124_CR45","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1084\/jem.183.6.2681","volume":"183","author":"JJ Costa","year":"1996","unstructured":"Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 1996;183:2681\u20136.","journal-title":"J Exp Med"},{"key":"1124_CR46","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood.V98.7.2200","volume":"98","author":"WR Sperr","year":"2001","unstructured":"\u2022 Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001;98:2200\u20139. This manuscript describes that tryptase is produced in immature myeloid blast cells in patients with acute myeloid leukemia (AML) and that in some of the AML patients, basal serum tryptase levels may be clearly elevated or even very high.","journal-title":"Blood"},{"key":"1124_CR47","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1158\/1078-0432.CCR-05-0732","volume":"11","author":"WR Sperr","year":"2005","unstructured":"Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, J\u00e4ger U, Lechner K, Valent P. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res. 2005;11:6536\u201343.","journal-title":"Clin Cancer Res"},{"key":"1124_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000501079","volume":"180","author":"P Valent","year":"2019","unstructured":"Valent P, Bonadonna P, Hartmann K, Broesby-Olsen S, Brockow K, Butterfield JH, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180:44\u201351.","journal-title":"Int Arch Allergy Immunol"},{"key":"1124_CR49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/all.13663","volume":"74","author":"T Boehm","year":"2019","unstructured":"Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B. Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients. Allergy. 2019;74:583\u201393.","journal-title":"Allergy"},{"issue":"23","key":"1124_CR50","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.3390\/ijms21239030","volume":"21","author":"P Valent","year":"2020","unstructured":"Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020;21(23):9030.","journal-title":"Int J Mol Sci"},{"key":"1124_CR51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18176\/jiaci.0675","volume":"31","author":"A Matito","year":"2021","unstructured":"Matito A, Escribese MM, Longo N, Mayorga C, Luengo-S\u00e1nchez O, P\u00e9rez-Gordo M, et al. Clinical approach to mast cell activation syndrome: a practical overview. J Investig Allergol Clin Immunol. 2021;31:461\u201370.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"1124_CR52","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","volume":"149","author":"A Mateja","year":"2022","unstructured":"Mateja A, Wang Q, Chovanec J, Kim J, Wilson KJ, Schwartz LB, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol. 2022;149:1010-17.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR53","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1111\/all.13226","volume":"72","author":"RL Baretto","year":"2017","unstructured":"\u2022 Baretto RL, Beck S, Heslegrave J, Melchior C, Mohamed O, Ekbote A. Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective. Allergy. 2017;72:2031\u20134. This manuscript confirms the value of the 120%+2 ng\/mL equation in patients with perioperative mast cell activation-related events (anaphylaxis).","journal-title":"Allergy"},{"key":"1124_CR54","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1016\/j.jaip.2021.03.050","volume":"9","author":"DG Ebo","year":"2021","unstructured":"Ebo DG, De Puysseleyr LP, Van Gasse AL, Elst J, Poorten MV, Faber MA, et al. Mast cell activation during suspected perioperative hypersensitivity: a need for paired samples analysis. J Allergy Clin Immunol Pract. 2021;9:3051-59.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4168\/aair.2014.6.4.304","volume":"6","author":"P Wongkaewpothong","year":"2014","unstructured":"Wongkaewpothong P, Pacharn P, Sripramong C, Boonchoo S, Piboonpocanun S, Visitsunthorn N, et al. The utility of serum tryptase in the diagnosis of food-induced anaphylaxis. Allergy Asthma Immunol Res. 2014;6:304\u20139.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1124_CR56","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jaci.2015.09.001","volume":"137","author":"S De Schryver","year":"2016","unstructured":"De Schryver S, Halbrich M, Clarke A, La Vieille S, Eisman H, Alizadehfar R, et al. Tryptase levels in children presenting with anaphylaxis: temporal trends and associated factors. J Allergy Clin Immunol. 2016;137:1138\u201342.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR57","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jaip.2018.01.006","volume":"6","author":"S Dua","year":"2018","unstructured":"Dua S, Dowey J, Foley L, Islam S, King Y, Ewan P, Clark AT. Diagnostic value of tryptase in food allergic reactions: a prospective study of 160 adult peanut challenges. J Allergy Clin Immunol Pract. 2018;6:1692-98.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR58","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez de Olano D, de la Hoz Caballer B, N\u00fa\u00f1ez L\u00f3pez R, S\u00e1nchez Mu\u00f1oz L, Cuevas Agust\u00edn M, Di\u00e9guez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547\u201355.","DOI":"10.1111\/j.1365-2222.2007.02804.x"},{"key":"1124_CR59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","volume":"123","author":"P Bonadonna","year":"2009","unstructured":"Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11882-009-0080-8","volume":"10","author":"C Akin","year":"2010","unstructured":"Akin C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep. 2010;10:34\u20138.","journal-title":"Curr Allergy Asthma Rep"},{"key":"1124_CR61","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226\u201332.","journal-title":"Allergy"},{"key":"1124_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0750-7658(05)81026-3","volume":"12","author":"J Watkins","year":"1993","unstructured":"Watkins J, Wild G. Improved diagnosis of anaphylactoid reactions by measurement of serum tryptase and urinary methylhistamine. Ann Fr Anesth Reanim. 1993;12:169\u201372.","journal-title":"Ann Fr Anesth Reanim"},{"key":"1124_CR63","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJM198312293092603","volume":"309","author":"JJ Keyzer","year":"1983","unstructured":"Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983;309:1603\u20135.","journal-title":"N Engl J Med"},{"key":"1124_CR64","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0091-6749(94)90371-9","volume":"93","author":"JA Awad","year":"1994","unstructured":"Awad JA, Morrow JD, Roberts LJ. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol. 1994;93:817\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"1124_CR65","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1398-9995.2007.01616.x","volume":"63","author":"E Ono","year":"2008","unstructured":"Ono E, Taniguchi M, Mita H, Akiyama K. Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite. Allergy. 2008;63:480\u20132.","journal-title":"Allergy"},{"key":"1124_CR66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","volume":"2","author":"A Ravi","year":"2014","unstructured":"Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1. J Allergy Clin Immunol Pract. 2014;2:775\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1124_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124912","volume":"10","author":"M Vysniauskaite","year":"2015","unstructured":"Vysniauskaite M, Hertfelder HJ, Oldenburg J, Dre\u00dfen P, Brettner S, Homann J, Molderings GJ. Determination of plasma heparin level improves identification of systemic mast cell activation disease. PLoS ONE. 2015;10: e0124912.","journal-title":"PLoS ONE"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01124-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01124-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T05:09:49Z","timestamp":1711170589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01124-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01124-2","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"3 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Peter Valent: received 1. a research grant from AOP Orphan and Celgene (BMS), and 2. consultancy honoraria from Novartis, Celgene, AOP Orphan, Blueprint, Pfizer, Stemline, and Cogent.  Cem Akin: received 1. a research grant from Blueprint and Cogent, and 2. consultancy honoraria from Blueprint, Cogent, and Novartis. Michel Arock received 1. a research grant from Blueprint, and 2. consultancy honoraria from AB Science, Blueprint, Novartis, and ThermoFisher.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The Fig.\u00a0\n                      \n                      is an original Figure and has never been published before.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Figure Originality Statement"}}]}}